Literature DB >> 717456

Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma.

S A Gall, P J DiSaia, H Schmidt, L Mittelstaedt, P Newman, W Creasman.   

Abstract

Manifestations of clinical toxicity were evaluated following 341 courses of intravenous Corynebacterium parvum adjuvant immunotherapy in patients with ovarian and cervical carcinoma. Most patients exhibited symptoms of minor toxicity, which decreased in intensity as subsequent courses of therapy were administered. Temperature elevations to 38.5 degrees C. were the most objectively measured signs of toxicity but temperature elevations greater than 38.5 degrees C. occurred following only 20.5 per cent of the infusions. Blood pressure alterations were not a serious problem and no serious central nervous system or renal toxicity was noted. The minor side effects should not preclude the use of C. parvum as an immunopotentiating agent if it is shown to be beneficial in the treatment of human malignant disease.

Entities:  

Mesh:

Year:  1978        PMID: 717456     DOI: 10.1016/0002-9378(78)90752-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Acute polyarthritis following the use of Corynebacterium parvum vaccine (Coparvax) for malignant pleural effusion.

Authors:  A M Lever; J Forsythe; P Oxford
Journal:  Postgrad Med J       Date:  1983-12       Impact factor: 2.401

Review 2.  Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.

Authors:  Mona W Schmidt; Marco J Battista; Marcus Schmidt; Monique Garcia; Timo Siepmann; Annette Hasenburg; Katharina Anic
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.